VivoSim Labs, Inc. (ONVO)

Overview

Organovo Holdings, Inc. is a pioneering biotechnology firm that has dedicated its efforts towards the creation of 3D tissues that closely mimic the essential characteristics of human diseases. The foundation of the company's innovative approach lies in its distinctive 3D human tissue platform, which incorporates the state-of-the-art NovoGen Bioprinters. These automated devices are paramount in the fabrication of 3D living tissues made from mammalian cells. The technology enables a groundbreaking method for producing multicellular tissues with intricate architectures, employing advanced bio-inks and bioprinting techniques. Established in 2007, Organovo has its headquarters firmly based in San Diego, California, where it continues to lead in the advancement of bioprinting technology for medical research and therapeutic applications.

Products and Services

• ExVive 3D Bioprinted Human Liver Tissue: This product symbolizes a significant breakthrough in the field of bioprinting and biomedical research. The ExVive 3D bioprinted human liver tissue is crafted to feature distinct compartments that replicate the hepatocellular (liver cells) and non-parenchymal cell environments found within the human liver. This innovation enables researchers and pharmaceutical companies to study the effects of drugs, diseases, and toxins on the liver in a more accurate and human-relevant system.

  The availability of such advanced 3D bioprinted tissues aids in reducing the reliance on animal models, providing a closer approximation to human physiological responses. It serves not only as a powerful tool for drug discovery and toxicity testing but also holds potential for future applications in therapeutic liver tissue patches or full liver organ replacement therapies.